Program Highlights

​Get a preview into the topics being discussed in the following sessions from the speakers who will be presenting:


Plenary Session 1:
Antophospholipid Syndrome

​Monday 27 November 2017
8:00-10:00

Mary-Carmen Amigo, Mexico






Mary-Carmen Amigo
The heart and APS

The heart is a target organ in APS. Valvular lesion is a potential source of cardioembolism to CNS. Heart valve lesion associated to aPL should be considered criteria for APS.

Understand the characteristics, evolution, and importance of the cardiac manifestations in APS. 

Read More:
Abreu MM et al. Autoimmunity Rev 2015;14:401-414
​El corazón en el SAF

Mostrar las características, evolución e importancia del compromiso cardíaco en el SAF.

Lee Más:
Abreu MM et al. Autoimmunity Rev 2015;14:401-414


​Parallel Session 1:
Systemic Autoimmune Diseases

​Monday 27 November 2017
10:40-12:40

Gabriela Medina, Mexico



Metabolic syndrome, autoimmunity and autoimmune rheumatic diseases

Metabolic syndrome (MetS) has increased in the last years throughout the world. Its prevalence is high among autoimmune rheumatic disease patients, leading to cardiovascular disease and consequently to death.

Mechanisms of interaction among MetS, autoimmunity and autoimmune rheumatic disease will be discussed, as well as preventive strategies.

Read more:
Medina G, Gutiérrez-Moreno AL, Vera-Lastra O, Saavedra MA, Jara LJ.Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients. Autoimmun Rev. 2011;10: 214-7.
​Síndrome metabólico, autoinmunidad y enfermedades reumáticas autoinmunes

El síndrome metabólico se ha incrementado en los últimos años a través del mundo.Su prevalencia es elevada entre los pacientes con enfermedades reumáticas autoinmunes (ERA), originando enfermedad cardiovascular y consecuentemente la muerte.Mecanismos de interacción entre MetS, autoinmunidad y ERA se discutirán, así como las estrategias terapéuticas.

Lee Más:
Medina G, Gutiérrez-Moreno AL, Vera-Lastra O, Saavedra MA, Jara LJ.Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients. Autoimmun Rev. 2011;10: 214-7.


Parallel Session 2: Autoantibody Updates

Monday 27 November 2017
10:40-12:40

Jose A Gómez-Puerta, Colombia


​Differences among ACPA positive and ACPA negative Rheumatoid arthritis patients

ACPA antibodies are the hallmark of RA. ACPA antibodies are not only useful markers for diagnosis (in early RA and established RA) but also for prognosis.

More recently, ACPA antibodies have been described as differential marker of clinical response in some non Anti-TNF therapies. Some clinical, histological and radiographic differences among RA ACPA positive or ACPA negative, will be discussed in detail during this session.

Read More:
https://arthritis-research.biomedcentral.com/
Diferencias entre los pacientes con Artritis Reumatoide ACPA positivos y ACPA negativos

Lee Más:
https://arthritis-research.biomedcentral.com/


​Parallel Session 4: Systemic Lupus Erythematosus

​Tuesday 28 November 2017
10:40-12:40

Jose A Gómez-Puerta, Colombia



​Urinary biomarkers in SLE

The knowledge of biomarkers is crucial for practicioners in charge of patiens with autoimmune diseases, including SLE.

Interest on the study of biomarkers in lupus is increasing during last years.

Our aim is to discuss the main urinary biomarkers related with lupus nephritis and to understand their clinical relevance and correlations with different classes of lupus nephritis on kidney biopsies.
Biomarcadores en la nefriris lúpica

El estudio de los diferentes biomarcadores en lupus ha despertado el interés de los investigadores durante los últimos años. El objetivo de la charla es discutir los principales biomarcadores en orina en la nefritid lúpica, su utilidad clínica y su correlación con las diferentes clases de nefritis lúpica en la biopsia renal.

​Plenary Session 5: The Environment in Autoimmunity

​Wednesday 29 November 2017
8:00-10:00

​ Monica Vazquez del Mercado, Mexico


monica.jfif


Obesity, autoimmunity, and autoimmune diseases 

Obesity as a worldwide epidemic, it must be considered as an important factor in autoimmune rheumatic diseases beyond an altered metabolic state, as an important contributor able to unbalance the clinical activity of theses diseases.

The session will discuss the role of leptin balance (soluble leptine and leptin receptor), obesity, ACPA and increase in the clinical activity of Rheumatoid Arthritis without comobomidities

Read More:
Vazquez-Del Mercado M. Pubmed
Obesidad, Autoinmunidad y Enfermedades Autoinmunes

Se discutirá la asociación de los niveles de leptina soluble, receptor soluble de leptina, obesidad, títulos de  anti CCP con el incremento de la actividad clinica en Artritis Reumatoide sin comorbidos pre-existentes. 

Lee Más:
Vazquez-Del Mercado M. Pubmed

Plenary Session 6: Advances in Autoimmune Disease Therapy 

Wednesday 29 November 2017
10:40-12:40

Simone Appenzeller, Brazil



Role of antibodies and cytokines in CNS manifestations in SLE

NP SLE is frequently observed and is a challenge in clinical practice.

In this session, the role of antibodies and cytokines in NP SLE will be discussed.

Main mimickers of NP SLE will be presented. 








Keep Me Updated